Trust Point Inc. Purchases 548 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Trust Point Inc. increased its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 28.3% during the 4th quarter, HoldingsChannel.com reports. The fund owned 2,483 shares of the company’s stock after buying an additional 548 shares during the period. Trust Point Inc.’s holdings in Neurocrine Biosciences were worth $339,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Plato Investment Management Ltd grew its position in Neurocrine Biosciences by 2,481.9% in the 3rd quarter. Plato Investment Management Ltd now owns 10,973 shares of the company’s stock worth $1,263,000 after purchasing an additional 10,548 shares during the last quarter. Swiss National Bank grew its position in Neurocrine Biosciences by 1.4% in the 3rd quarter. Swiss National Bank now owns 298,700 shares of the company’s stock worth $34,416,000 after purchasing an additional 4,100 shares during the last quarter. Tri Ri Asset Management Corp acquired a new stake in Neurocrine Biosciences in the 3rd quarter worth $3,236,000. KBC Group NV grew its position in Neurocrine Biosciences by 78.3% in the 3rd quarter. KBC Group NV now owns 18,972 shares of the company’s stock worth $2,186,000 after purchasing an additional 8,332 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. grew its position in Neurocrine Biosciences by 64.3% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 19,421 shares of the company’s stock worth $2,238,000 after purchasing an additional 7,597 shares during the last quarter. 92.59% of the stock is currently owned by institutional investors and hedge funds.

Neurocrine Biosciences Trading Down 0.8 %

Shares of NASDAQ NBIX opened at $151.20 on Thursday. Neurocrine Biosciences, Inc. has a 1-year low of $110.95 and a 1-year high of $157.98. The company has a market cap of $15.31 billion, a PE ratio of 40.54 and a beta of 0.33. The company has a 50-day moving average of $137.92 and a two-hundred day moving average of $131.51.

Analyst Upgrades and Downgrades

Several analysts have issued reports on NBIX shares. StockNews.com lowered shares of Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a research report on Friday, November 1st. UBS Group lifted their target price on shares of Neurocrine Biosciences from $162.00 to $176.00 and gave the company a “buy” rating in a research report on Thursday, January 30th. Needham & Company LLC reiterated a “hold” rating on shares of Neurocrine Biosciences in a research report on Friday, December 20th. Morgan Stanley lifted their target price on shares of Neurocrine Biosciences from $170.00 to $185.00 and gave the company an “overweight” rating in a research report on Tuesday. Finally, William Blair reiterated an “outperform” rating on shares of Neurocrine Biosciences in a research report on Monday, December 16th. Five investment analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Neurocrine Biosciences currently has a consensus rating of “Moderate Buy” and a consensus price target of $166.85.

Insiders Place Their Bets

In related news, insider Jude Onyia sold 2,331 shares of the business’s stock in a transaction that occurred on Friday, November 29th. The shares were sold at an average price of $126.29, for a total transaction of $294,381.99. Following the completion of the sale, the insider now directly owns 15,449 shares of the company’s stock, valued at $1,951,054.21. The trade was a 13.11 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Kevin Charles Gorman sold 146,105 shares of the business’s stock in a transaction that occurred on Monday, January 27th. The stock was sold at an average price of $149.46, for a total transaction of $21,836,853.30. Following the sale, the director now directly owns 514,596 shares of the company’s stock, valued at approximately $76,911,518.16. This trade represents a 22.11 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 222,693 shares of company stock valued at $32,718,279. Insiders own 4.30% of the company’s stock.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.